scholarly journals Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis

2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Ana Silvia Corlan ◽  
Anca Maria Cîmpean ◽  
Adriana-Andreea Jitariu ◽  
Eugen Melnic ◽  
Marius Raica

A lot of data suggests endocrine gland-derived vascular endothelial growth factor (EG-VEGF) to be restricted to endocrine glands and to some endocrine-dependent organs. Many evidences show that EG-VEGF stimulates angiogenesis and cell proliferation, although it is not a member of the VEGF family. At the time, a lot of data regarding the role of this growth factor in normal development are available. However, controversial results have been published in the case of pathological conditions and particularly in malignant tumors. Thus, our present paper has been focused on the role of EG-VEGF in normal tissues and various malignant tumors and their angiogenic processes.

2019 ◽  
Vol 2 (1) ◽  
pp. 27-37
Author(s):  
Aziz Alsohaimi

Vascular endothelial growth factor (VEGF), first isolated in 1989, is now considered the key mediator for the process of angiogenesis involved in many developmental, physiological, and pathological conditions. Studies have shown that VEGF family consists of 5 isoforms with similar biological activity but differ in their target receptor activity; the most important of them being the VEGF-A. Studies have also defined the presence of 3 types of VEGF receptors predominantly located on vascular endothelial, stromal, and hematopoietic cells. Recent research has shed light on VEGF as a key mediator of angiogenesis in many pathological conditions such as tumor growth and metastasis. Likewise, there have been intensive efforts to clarify the pathogenic role of VEGF/VEGFRs in skin diseases. VEGF and its receptors are also investigated as pivotal players in many skin diseases such as psoriasis, atopic dermatitis, chronic inflammatory skin diseases, phototoxicity, and dysregulated differentiation/proliferation of dermal and epidermal cells. Therefore, in this review, we will discuss the implication of VEGF as a pathogenic biomarker for skin disorders by discussing the available experimental and clinical evidences for the potential role of VEGF in some dermatologic disorders.


2015 ◽  
Vol 6 (5-6) ◽  
pp. 225-236 ◽  
Author(s):  
Dorothee Heck ◽  
Sebastian Wortmann ◽  
Luitgard Kraus ◽  
Cristina L. Ronchi ◽  
Richard O. Sinnott ◽  
...  

JHEP Reports ◽  
2021 ◽  
Vol 3 (3) ◽  
pp. 100251
Author(s):  
Valeria Mariotti ◽  
Romina Fiorotto ◽  
Massimiliano Cadamuro ◽  
Luca Fabris ◽  
Mario Strazzabosco

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 253
Author(s):  
Xi Guo ◽  
Hong Yi ◽  
Tin Chiu Li ◽  
Yu Wang ◽  
Huilin Wang ◽  
...  

Vascular endothelial growth factor (VEGF) is a well-known angiogenic factor that plays a critical role in various physiological and pathological processes. VEGF also contributes to the process of embryo implantation by enhancing embryo development, improving endometrial receptivity, and facilitating the interactions between the developing embryo and the endometrium. There is a correlation between the alteration of VEGF expression and reproductive failure, including recurrent implantation failure (RIF) and recurrent miscarriage (RM). In order to clarify the role of VEGF in embryo implantation, we reviewed recent literature concerning the expression and function of VEGF in the reproductive system around the time of embryo implantation and we provide a summary of the findings reported so far. We also explored the effects and the possible underlying mechanisms of action of VEGF in embryo implantation.


2017 ◽  
Vol 68 (4) ◽  
pp. 326-329
Author(s):  
Piotr Barć ◽  
Tomasz Płonek ◽  
Dagmara Baczyńska ◽  
Artur Pupka ◽  
Wojciech Witkiewicz ◽  
...  

2007 ◽  
Vol 116 (6) ◽  
pp. 430-435 ◽  
Author(s):  
Reza Rahbar ◽  
Lawrence F. Brown ◽  
Judah Folkman ◽  
Trevor J. McGill ◽  
Gerald B. Healy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document